Tenax’s TNX-103 Misses Primary Endpoint in Late-Stage Heart Failure Trial
Tenax’s heart drug trial missed its main goal, but showed promise in sicker patients, sending shares down more than 85%.
/ 352 items
#XY Event-Driven Stocks↓
Sionna Therapeutics Stock Plunges After Cystic Fibrosis Trial Failure; Vertex Rises on Reduced Competition
Will not advance SION-719 add-on; Vertex sees relief from rivalry.
AbCellera’s Single-Dose Menopause Treatment Delivers Big Reduction in Hot Flashes
AbCellera shares jumped after its menopause drug reduced hot flashes by 83% in a Phase 2 trial, with no serious side effects reported.
Varex Imaging Shares Surge 49% After Teledyne Agrees to $1.1 Billion Acquisition
Teledyne will acquire Varex Imaging for $18.90 per share.
Innate Pharma Partners with Sobi to Advance Lacutamab into Phase 3 for Rare T-Cell Lymphoma
Innate Pharma teams up with Sobi to launch TELLOMAK-3 Phase 3 trial of lacutamab for rare T-cell lymphoma, with $75M upfront and new CMO.
Why Replimune Shares Dropped Despite FDA Nod for Melanoma Drug TUDRIQEV
Investors reacted to the 24.2% ORR on the official label.